Caribou Biosciences, Inc. Common Stock (CRBU) Stock Price

CRBUStock

$1.76−11.35%52W

Market Cap$188.69M

P/E—

PEG Ratio—

Div yield—

Beta2.37

CRBU Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-10.01%

Price vs S&P 500 (4W)7.02%

VGM Score45.91

Book Value / Share (Quarterly)$1.05

P/TBV (Annual)1.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-6.95%

Cash Flow / Share (Quarterly)$-1.05

Price vs S&P 500 (YTD)-8.81%

Net Profit Margin (TTM)-1189.14%

EPS (TTM)$-1.42

10-Day Avg Trading Volume0.99M

EPS Excl Extra (TTM)$-1.42

Revenue Growth (5Y)-2.02%

EPS (Annual)$-1.59

ROI (Annual)-121.24%

Net Profit Margin (5Y Avg)-906.06%

Cash / Share (Quarterly)$1.21

Revenue Growth QoQ (YoY)1.87%

ROA (Last FY)-84.47%

Revenue Growth TTM (YoY)12.96%

EBITD / Share (TTM)$-1.46

ROE (5Y Avg)-51.64%

Operating Margin (TTM)-1257.42%

Cash Flow / Share (Annual)$-1.18

P/B Ratio1.57x

P/B Ratio (Quarterly)1.80x

Net Income / Employee (Annual)$-1,527,100

EV / Revenue (TTM)13.18x

Net Interest Coverage (TTM)-16978.50x

ROA (TTM)-71.99%

EPS Incl Extra (Annual)$-1.59

Current Ratio (Annual)5.71x

Quick Ratio (Quarterly)6.10x

3-Month Avg Trading Volume1.78M

52-Week Price Return-11.35%

Revenue / Employee (TTM)$115,500

Tangible BV / Share (Quarterly)$4.50

P/S Ratio (Annual)14.31x

Asset Turnover (Annual)0.06x

52-Week High$3.54

Operating Margin (5Y Avg)-972.94%

EPS Excl Extra (Annual)$-1.59

CapEx CAGR (5Y)33.54%

26-Week Price Return1.23%

Quick Ratio (Annual)5.60x

13-Week Price Return-17.59%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.22x

Enterprise Value$147.62M

Revenue / Share Growth (5Y)-11.33%

Asset Turnover (TTM)0.06x

Revenue / Employee (Annual)$115,000

Pretax Margin (Annual)-1332.33%

Cash / Share (Annual)$1.46

3-Month Return Std Dev59.72%

Net Income / Employee (TTM)$-1,373,400

ROE (Last FY)-121.24%

Net Interest Coverage (Annual)-852.54x

EPS Basic Excl Extra (Annual)$-1.59

Receivables Turnover (TTM)12.35x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.42

Receivables Turnover (Annual)6.51x

ROI (TTM)-100.13%

P/S Ratio (TTM)14.25x

Pretax Margin (5Y Avg)-906.19%

Revenue / Share (Annual)$0.12

Tangible BV / Share (Annual)$4.93

Price vs S&P 500 (52W)-29.66%

Year-to-Date Return3.14%

5-Day Price Return5.13%

EPS Normalized (Annual)$-1.59

ROA (5Y Avg)-39.48%

Net Profit Margin (Annual)-1327.40%

Month-to-Date Return12.33%

Cash Flow / Share (TTM)$-1.36

EBITD / Share (Annual)$-1.65

Operating Margin (Annual)-1411.43%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-51.64%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.42

P/TBV (Quarterly)1.26x

P/B Ratio (Annual)1.22x

Pretax Margin (TTM)-1194.05%

Book Value / Share (Annual)$1.28

Price vs S&P 500 (13W)-20.38%

Beta2.37x

Revenue / Share (TTM)$0.12

ROE (TTM)-100.13%

52-Week Low$1.38

vGradeC

gGradeC

mGradeC

vgmGradeC

CRBU Earnings Surprise History

Q2 25-0.35est. -0.42

Q3 25-0.30est. -0.36

Q4 25-0.28est. -0.32

Q1 26-0.26est. -0.31

Q2 26-0.24est. -0.31

CRBU Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.27

4.29

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRBUCaribou Biosciences, Inc. Common Stock	C	C	C	$1.76
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Caribou Biosciences, Inc. Common Stock

Caribou Biosciences is a clinical-stage CRISPR biopharmaceutical company developing next-generation cell therapies using its proprietary chRDNA platform. The company focuses on creating allogeneic CAR-T and CAR-NK cell therapies designed to treat patients with serious diseases. Caribou's genome-editing approach aims to overcome existing limitations in cell-based cancer therapeutics.